Celcuity (CELC) to Release Earnings on Wednesday

Key Points

• Celcuity will report Q1 2026 results after the market close on Wednesday, May 13, with analysts projecting ($1.07) EPS and about $2.94M in revenue.
• Topline Phase 3 VIKTORIA‑1 results reportedly showed gedatolisib improved progression‑free survival versus Novartis’ alpelisib in the PIK3CA‑mutant cohort, prompting the company to pursue a supplemental NDA and spurring analyst target increases.
• Despite the clinical catalysts, the stock carries a high valuation (market cap ≈ $6.85B) with negative EPS and recent insider selling, highlighting potential volatility and downside risk if upcoming ASCO or FDA updates disappoint.

Celcuity (NASDAQ:CELC - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Celcuity to post earnings of ($1.07) per share and revenue of $2.9390 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.09. On average, analysts expect Celcuity to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Celcuity Stock Down 2.3%

CELC stock opened at $141.69 on Wednesday. The business's 50-day moving average price is $115.27 and its 200-day moving average price is $103.28. The stock has a market cap of $6.85 billion, a P/E ratio of -37.39 and a beta of 0.09. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. Celcuity has a twelve month low of $9.51 and a twelve month high of $151.02.

Insiders Place Their Bets

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at $745,425.20. This represents a 30.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by insiders.

Hedge Funds Weigh In On Celcuity

Hedge funds have recently modified their holdings of the stock. US Bancorp DE grew its stake in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. Aristides Capital LLC lifted its stake in Celcuity by 2.0% in the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company's stock worth $1,526,000 after purchasing an additional 303 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in Celcuity by 4.2% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 8,637 shares of the company's stock worth $861,000 after purchasing an additional 350 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Celcuity during the 4th quarter valued at about $42,000. Finally, Rhumbline Advisers boosted its holdings in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock valued at $570,000 after purchasing an additional 503 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company's stock.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Topline Phase 3 VIKTORIA‑1 results reportedly show gedatolisib improved progression‑free survival vs Novartis’ alpelisib in the PIK3CA‑mutant cohort — a direct efficacy win versus a marketed competitor that materially strengthens commercial prospects. Celcuity’s gedatolisib beats Novartis drug in Phase III test
• Positive Sentiment: Company says it will pursue a supplemental NDA filing for the PIK3CA‑mutant data and will present detailed results at ASCO — this creates a clear near‑term regulatory/visibility catalyst on top of the already accepted NDA for a different subgroup. Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib
• Positive Sentiment: Multiple analysts raised ratings/targets after the news (Needham to $157, Citizens/JMP to $160 and others), which likely amplified buying and gave investors new valuation anchors. Needham & Company LLC Issues Positive Forecast for Celcuity NASDAQ: CELC Stock Price
• Neutral Sentiment: Broad media coverage (MarketWatch, FierceBiotech, Yahoo/Finance) is increasing awareness ahead of ASCO and the upcoming PDUFA for the previously accepted NDA, pushing volumes and short‑term attention. Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results
• Neutral Sentiment: Clinical summaries and independent coverage recap VIKTORIA‑1 toplines and planned ASCO presentation; these reports inform but leave detailed subgroup and safety readouts pending (ASCO presentation will be important). Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
• Negative Sentiment: Insider selling has been reported recently (multiple open‑market sales), which some investors view as a cautionary signal despite positive trial news. Insider trading and institutional flow summary
• Negative Sentiment: High valuation and negative reported EPS mean the stock’s rally rests on future commercial execution and regulatory approvals; volatility and downside risk remain if upcoming ASCO or FDA updates disappoint. Valuation note

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Guggenheim raised their target price on shares of Celcuity from $135.00 to $165.00 and gave the stock a "buy" rating in a research note on Monday. Wall Street Zen cut shares of Celcuity from a "hold" rating to a "sell" rating in a research note on Saturday, April 25th. Craig Hallum restated a "buy" rating and set a $189.00 price objective on shares of Celcuity in a research report on Monday. Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a research note on Monday. Finally, Citizens Jmp upped their target price on shares of Celcuity from $150.00 to $160.00 and gave the stock a "market outperform" rating in a report on Monday. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $134.50.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.